Rimegepant (Nurtec ODT) for Acute Treatment of Migraine

Date: May 4, 2020 Issue #:  1597Summary:  The FDA has approved an orally disintegrating tablet (ODT) formulation of rimegepant (Nurtec ODT– Biohaven), a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ( " gepant " ), for acute treatment of migraine with or without aura in adults. Rimegepant is the second oral gepant to become available in the US; ubrogepant(Ubrelvy), which is approved for the same indication, was the first. Four parenteral CGRP antagonists, erenumab(Aimovig), fremanezumab(Ajovy), galcanezumab(Emgality), and eptinezumab(Vyepti), are approved for prevention of migraine.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Aimovig Ajovy Emgality eptinezumab erenumab fremanezumab galcanezumab Imitrex Migraine NSAIDs Nurtec ODT rimegepant Sumatriptan Ubrelvy ubrogepant Vyepti Source Type: research